Breaking News

DSM, Crucell License PER.C6 To Masterclone

DSM and Crucell entered a non-exclusive PER.C6 research licensing agreement with Russia-based Masterclone. Masterclone will use Crucell’s technology to develop an undisclosed antibody. Financial details were not disclosed.

The PER.C6 technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as vaccines and proteins.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters